P1/2, N=139, Recruiting, LaNova Medicines Limited | Suspended --> Recruiting | Trial completion date: Aug 2025 --> Jan 2028 | Trial primary completion date: Dec 2024 --> Jan 2027

3 days ago

Enrollment open • Trial completion date • Trial primary completion date • Metastases

Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • LM-101

12ms

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=145, Suspended, LaNova Medicines Limited

12 months ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101

1year

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=145, Suspended, LaNova Medicines Limited | Recruiting --> Suspended

1 year ago

Trial suspension • Combination therapy • Metastases

Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101

almost2years

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=145, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting

almost 2 years ago

Enrollment open • Combination therapy • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)

Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101

2years

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov)

P1/2, N=145, Not yet recruiting, LaNova Medicines Limited

2 years ago

New P1/2 trial • Combination therapy • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)

Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101